Bio-Rad Laboratories, Inc. Stock

Equities

BIO

US0905722072

Medical Equipment, Supplies & Distribution

Market Closed - Nyse 04:00:02 2024-07-19 pm EDT 5-day change 1st Jan Change
296.8 USD -1.15% Intraday chart for Bio-Rad Laboratories, Inc. -2.41% -8.07%
Sales 2024 * 2.66B Sales 2025 * 2.8B Capitalization 8.45B
Net income 2024 * 294M Net income 2025 * 285M EV / Sales 2024 * 2.92 x
Net cash position 2024 * 674M Net cash position 2025 * 828M EV / Sales 2025 * 2.73 x
P/E ratio 2024 *
28.8 x
P/E ratio 2025 *
29.7 x
Employees 8,030
Yield 2024 *
-
Yield 2025 *
-
Free-Float 66.04%
More Fundamentals * Estimated data
Dynamic Chart
Bio-Rad Laboratories, Inc.(NYSE:BIO) added to Russell 2500 Value Index CI
Bio-Rad Laboratories, Inc.(NYSE:BIO) added to Russell 2500 Index CI
RBC Trims Price Target on Bio-Rad Laboratories to $402 From $414, Keeps Outperform Rating MT
OncoCyte Corporation announced that it expects to receive $3.5 million in funding from Bio-Rad Laboratories, Inc. CI
Transcript : Bio-Rad Laboratories, Inc. Presents at Jefferies 2024 Global Healthcare Conference, Jun-06-2024 10:30 AM
Bio-Rad Laboratories, Inc. Appoints Anette Engelhardt as Executive Vice President and President of Clinical Diagnostics Group, Effective June 10, 2024 CI
Transcript : Bio-Rad Laboratories, Inc. Presents at 2024 RBC Capital Markets Global Healthcare Conference, May-14-2024 02:05 PM
UBS Adjusts Price Target on Bio-Rad Laboratories to $385 From $420, Maintains Buy Rating MT
RBC Adjusts Price Target on Bio-Rad Laboratories to $414 From $420 MT
Citigroup Adjusts Price Target on Bio-Rad Laboratories to $300 From $365 MT
Bio-Rad Laboratories reiterates 2024 revenue growth outlook; shares slip RE
Bio-Rad Laboratories Q1 Non-GAAP Earnings, Revenue Decline MT
Transcript : Bio-Rad Laboratories, Inc., Q1 2024 Earnings Call, May 07, 2024
Earnings Flash (BIO) BIO-RAD LABORATORIES Reports Q1 Revenue $610.8M, vs. Street Est of $620.1M MT
Earnings Flash (BIO) BIO-RAD LABORATORIES Reports Q1 EPS $2.29, vs. Street Est of $2.14 MT
More news
1 day-1.15%
1 week-2.41%
Current month+8.68%
1 month+3.92%
3 months+6.11%
6 months-3.20%
Current year-8.07%
More quotes
1 week
291.48
Extreme 291.48
323.17
1 month
262.12
Extreme 262.12
323.17
Current year
262.12
Extreme 262.12
364.24
1 year
261.59
Extreme 261.59
431.79
3 years
261.59
Extreme 261.59
832.70
5 years
261.59
Extreme 261.59
832.70
10 years
102.71
Extreme 102.71
832.70
More quotes
Managers TitleAgeSince
Chief Executive Officer 74 88-12-31
Director of Finance/CFO 77 83-01-31
Chief Operating Officer 64 19-04-21
Members of the board TitleAgeSince
Director/Board Member 63 17-04-24
Founder 97 51-12-31
Director/Board Member 77 17-04-24
More insiders
Date Price Change Volume
24-07-19 296.8 -1.15% 298,868
24-07-18 300.3 -5.77% 341,724
24-07-17 318.6 +1.31% 217,667
24-07-16 314.5 +4.11% 185,493
24-07-15 302.1 -0.67% 231,378

Delayed Quote Nyse, July 19, 2024 at 04:00 pm EDT

More quotes
Bio-Rad Laboratories, Inc. is specialized in the development, manufacturing and marketing of products used in life sciences research, clinical diagnostics and analytical chemistry. Net sales break down by activity as follows: - manufacture of clinical diagnostic tests and automated test systems (51.8%). The group also offers test kits, quality control systems and related IT systems; - manufacture of reagents, equipment and instruments for biological research (48.1%): for the separation, identification and purification of chemical and biological substances (proteins, nucleic acids, bacteria, etc.) for the proteomics, genomics research, biopharmaceuticals, cell biology and food safety markets; - other (0.1%): in particular, manufacturing of analytical instruments. At the end of 2022, the Group has 16 production sites in the United States (5), Germany (3), France (2), China (2), Poland, the United Kingdom, Switzerland and Singapore. Net sales are distributed geographically as follows: the United States (41.2%), Europe (30.4%), Asia (22.8%) and other (5.6%).
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
296.8 USD
Average target price
366.4 USD
Spread / Average Target
+23.44%
Consensus

Quarterly revenue - Rate of surprise